Industry verticals
Warm Introductions in Pharmaceutical and Biotech Market Access
Getting a new drug or biologic to patients depends less on prescriber demand than on formulary inclusion and payer coverage: decisions gated by clinical committees and medical directors who are structurally insulated from commercial promotion. The levers that move them are physician advocacy and payer peer influence, which is to say: warm introductions.
Why market access is a relationship problem, not a promotion problem
A pharmaceutical or biotech company can have FDA approval, compelling pivotal data, and a fully staffed commercial organisation and still fail to reach patients, because approval is permission to sell, not access to buyers. Access is controlled by two gates the manufacturer cannot walk through directly: the hospital and health-system formulary, decided by Pharmacy and Therapeutics (P&T) committees, and payer coverage, decided by medical directors at managed care organisations, pharmacy benefit managers, and integrated delivery network buying groups. Both gates are deliberative bodies that evaluate clinical evidence, comparative effectiveness, and budget impact, and both weight the endorsements of clinical voices they trust far above anything a manufacturer says on its own behalf.
This is a structural feature, not an accident. The separation of medical and commercial functions inside pharma, the constraints on promotional claims, the Sunshine Act’s public reporting of physician payments, and anti-kickback rules together ensure that direct commercial outreach has limited reach into the people who actually decide access. IQVIA’s analysis of drug launches has repeatedly linked the speed and breadth of early formulary and payer access to a product’s ultimate commercial trajectory, meaning the pathways that shorten time-to-access shape the entire launch, not just its margins.
The levers that actually move access are relational: the clinical advocacy of Key Opinion Leaders, the long-term scientific relationships clinical science liaisons build with prescribers, and the peer dynamics among payer medical directors. Each is a warm-introduction mechanic, and each works because of where its actors sit in the network rather than what they are paid to say. The three mechanics below are how a new therapy actually crosses from approval to access.
Three mechanics for reaching market-access decision-makers
The KOL introduction as clinical bridge
Key Opinion Leaders (academic department heads, principal investigators on pivotal trials, specialty society leaders) carry influence over formulary thinking that no commercial function can manufacture. When a respected academic oncologist presents pivotal data for a new biologic at ASCO, they are not selling; they are establishing clinical truth in front of the exact audience that P&T (Pharmacy and Therapeutics) committees and payer medical directors defer to. The endorsement travels along two bridges at once: into health systems, where the KOL sits on or advises the formulary committee, and into managed care, where medical directors read the same podium presentation as the definitive read on where the therapy fits in the treatment paradigm. A biologic that arrives at a P&T committee already carrying a named academic advocate is evaluated in a fundamentally different register than one that arrives as a manufacturer dossier alone. The KOL is a classic Granovetter bridge: a single tie that spans two otherwise weakly connected clusters (academic medicine and payer coverage decision-making), and because so few ties span that structural gap, the information and credibility that flow across it are disproportionately valuable.
How to build it: Identify the KOLs whose clinical authority is genuine and whose therapeutic focus aligns with the product, and build the relationship through the scientific channel long before launch: advisory boards, investigator meetings, data-generation collaboration, congress symposia. The endorsement cannot be bought and must not look bought (the compliance exposure alone forbids it); it has to be earned through data the KOL finds genuinely convincing. When the science supports it, the KOL becomes the bridge that carries the product into formulary and payer conversations the manufacturer could never enter directly.
The clinical science liaison as in-market connector
The regional Clinical Science Liaison (also called a Medical Science Liaison) is the pharmaceutical industry’s dedicated relationship-builder in the field: a scientifically trained, non-commercial role whose entire function is to maintain peer-to-peer scientific dialogue with community prescribers: oncologists, endocrinologists, cardiologists, rheumatologists practising outside the academic centres. Over years, the CSL becomes a trusted, low-pressure scientific resource for these physicians, answering off-label questions, sharing emerging data, connecting community prescribers to the academic KOLs who anchor the field. That accumulated trust is the connective tissue of market access: when a community oncologist already respects the CSL as a straight scientific interlocutor, and a KOL that oncologist admires has endorsed the therapy, the two signals converge into a formulary referral. The community physician advocates for the drug on their own hospital’s formulary, or prescribes it in a way that generates the utilisation data payers watch. The CSL is the weak-tie connector who bridges the academic centre and the community practice, and the value they carry is precisely a function of occupying that structural position between clusters that rarely talk directly.
How to build it: Deploy CSLs by therapeutic area and region with the mandate to build genuine long-term scientific relationships, not to hit call quotas. Measure the relationship, not the pitch: depth of scientific dialogue, the physician’s willingness to engage on emerging data, the CSL’s ability to connect a community prescriber to the right KOL. The referral to formulary is a downstream effect of a trust relationship that has to be real: a CSL treated as a disguised sales rep destroys the peer credibility the whole mechanic depends on.
The peer health-plan introduction
When one managed care medical director makes a positive coverage decision for a new therapy and mentions the reasoning at an AMCP (Academy of Managed Care Pharmacy) meeting or inside a payer collaborative, peer medical directors at other health plans take notice, and frequently follow. The mechanism is identical to the investor reference call in B2B SaaS or the peer-CFO conversation in enterprise software: a decision-maker facing an uncertain, high-stakes call reduces their risk by learning that a trusted peer, facing the same evidence and the same budget pressures, already decided one way. Coverage decisions are rarely made in isolation because the medical directors sit in a dense professional community (the same conferences, the same collaboratives, the same specialty forums) where candid peer conversation about what worked and what didn’t carries more weight than any manufacturer value dossier. A single early, well-reasoned coverage win, surfaced into that peer network, becomes an introduction currency that propagates across plans. This is trust transfer operating exactly as Van den Bulte and Wuyts describe it: credibility attached to the source (a respected peer medical director) transfers to the object of the endorsement (the coverage decision), lowering the perceived risk for the next adopter.
How to build it: Treat the first coverage wins as reference assets, not just revenue events. Secure medical directors who are willing, within the bounds of what payers permit, to share their coverage rationale in peer settings: AMCP sessions, payer advisory boards, published coverage-decision case studies in journals like JMCP. Sequence launch to earn a credible early win with an influential plan, then make its reasoning visible to the peer community rather than starting each plan from cold.
The market-access buyer: three structural facts
Understanding why warm introductions dominate market access requires understanding what makes the formulary and payer buyer structurally different from a commercial prospect.
The decision sits with a committee, not a prescriber
Formulary inclusion is decided by the P&T committee, a body of physicians, formulary pharmacists, and medical directors that evaluates clinical evidence, comparative effectiveness, and budget impact. AMCP research on P&T decision factors consistently finds that clinical evidence quality and the assessment of unmet need dominate, but that the interpretation of that evidence is heavily shaped by which clinical voices the committee trusts. The buyer is not a single person to be pitched; it is a deliberative body that weights endorsements from credible clinical sources far above manufacturer claims.
Access speed is correlated with launch trajectory
IQVIA analysis of drug launches has repeatedly linked the speed and breadth of formulary and payer access to the ultimate commercial trajectory of a therapy: products that secure broad favourable access early establish utilisation curves that later entrants struggle to overturn. Because access is gated by clinical advocacy and payer coverage rather than by prescriber demand alone, the introduction pathways that shorten time-to-access have outsized effect on the entire launch. A warm KOL or peer-payer pathway that compresses months off the access timeline is not a marketing nicety; it is a determinant of the launch curve.
Peer influence dominates payer coverage decisions
Research published in the Journal of Managed Care & Specialty Pharmacy on payer decision-making documents how coverage determinations propagate through the medical-director community: plans benchmark against peer plans, and a medical director weighing an uncertain call actively seeks the reasoning of trusted peers who have already decided. Fein’s Drug Channels analysis of specialty market access similarly emphasises that KOL influence and payer peer dynamics, rather than direct commercial promotion, are the primary levers for specialty and biologic access. The structural implication is that the coverage decision is a socially embedded judgment, not an isolated actuarial calculation.
The weak-tie bridge, applied to clinical and payer networks
Mark Granovetter’s work on the strength of weak ties explains why the KOL and the clinical science liaison carry such disproportionate value. The information and credibility that matter most in market access do not flow within a tightly connected cluster, where everyone already shares the same view, but across the sparse ties that bridge otherwise separate clusters. Academic medicine and payer coverage decision-making are two such clusters: dense internally, weakly connected to each other. A KOL who presents at ASCO and also advises formulary committees is one of the few ties spanning that gap, and because bridging ties are rare, what crosses them is uniquely influential. The clinical science liaison plays the same structural role between the academic centre and the community practice, a connector occupying the gap between clusters that rarely talk directly.
The peer health-plan introduction adds the trust-transfer layer that Van den Bulte and Wuyts, building on Schmitt’s work on referral dynamics, describe: the credibility attached to a trusted source transfers to the thing that source endorses, lowering the perceived risk for the next decision-maker. When a respected medical director’s coverage rationale reaches a peer weighing the same call, the peer inherits some of that credibility and decides faster and more favourably. Bridge position explains who can carry an endorsement across the structural gap; trust transfer explains why the endorsement changes the recipient’s decision once it arrives. Together they account for why market access is won through warm pathways and lost through cold ones.
Sequencing access: from evidence to advocacy to coverage
The three mechanics are not independent tactics; they compose into a sequence. It begins with data a credible clinical community genuinely finds convincing; without that, no compliant endorsement is possible and every downstream pathway is closed. It proceeds through the KOL relationships built via the scientific channel long before launch, so that when pivotal data reads out, respected academic voices are positioned to interpret it in front of P&T committees and payer medical directors. It runs in parallel through the clinical science liaison network, whose peer-to-peer relationships with community prescribers convert the academic endorsement into formulary referrals and real-world utilisation. And it culminates in the first payer coverage wins, which, surfaced credibly into the medical-director peer community at AMCP and payer collaboratives, propagate to peer plans rather than requiring each to be won from cold.
Every step of this sequence is gated by compliance, and that is a feature rather than an obstacle. The separation of medical and commercial functions, fair-market-value documentation, Sunshine Act reporting, and anti-kickback rules mean the advocacy that moves access cannot be manufactured through commercial incentives; it has to be earned through evidence and relationships that are scientifically real. A KOL endorsement moves a formulary committee precisely because the committee believes it reflects clinical judgment rather than a commercial arrangement. The companies that win market access are not the ones with the loudest promotion but the ones that generate the evidence and cultivate the relationships that let credible clinical and payer voices speak specifically, honestly, and at the right moment. The warm introduction, in this world, is the whole game.
FAQ
FAQs on pharmaceutical and biotech market-access introductions
Why does cold outreach fail in pharmaceutical and biotech market access?
Market access is not a transaction that a prescriber or a payer initiates in response to a pitch; it is a series of gated, committee-driven, evidence-weighted decisions made by people who are structurally insulated from commercial promotion. A P&T committee evaluates a formulary submission on clinical evidence and budget impact, and it weights the endorsements of clinical voices it trusts far above anything a manufacturer says directly. A payer medical director making a coverage decision is influenced far more by the reasoning of a trusted peer medical director than by a value dossier. Regulatory and compliance boundaries (the separation of commercial and medical functions, the constraints on promotional claims, the Sunshine Act reporting on physician payments) further limit what direct outreach can even do. The levers that actually move access are clinical advocacy from Key Opinion Leaders, the long-term scientific relationships that clinical science liaisons build with prescribers, and the peer dynamics among payer medical directors. All three are relationship pathways that cold promotion cannot replicate, and all three are exactly the warm-introduction mechanics that determine whether a therapy reaches patients quickly or slowly.
What is a Key Opinion Leader (KOL) and why does KOL endorsement matter so much?
A Key Opinion Leader is a physician whose clinical authority in a therapeutic area gives their assessment of a therapy disproportionate influence over how the broader medical and payer community thinks about it: typically academic department heads, principal investigators on pivotal trials, and specialty society leaders. KOL endorsement matters because market access decisions turn on the interpretation of clinical evidence, and P&T committees and payer medical directors defer to the clinical voices they consider most credible. When a respected academic oncologist presents pivotal data at a major congress like ASCO, that presentation shapes the treatment paradigm in the minds of the exact people who will later vote on formulary inclusion and coverage. In network terms, the KOL is a bridge spanning two weakly connected clusters (academic medicine and payer decision-making), and because so few ties span that gap, the credibility that flows across it is disproportionately valuable. The endorsement has to be earned through genuinely convincing data and structured through the compliant scientific channel; it cannot be purchased, and any appearance that it was would destroy both its credibility and expose the company to serious compliance risk.
How does a clinical science liaison (CSL) differ from a sales representative?
A clinical science liaison, also called a medical science liaison, is a scientifically trained, non-commercial field role whose function is peer-to-peer scientific dialogue with physicians, not selling. The distinction is not cosmetic: CSLs sit inside the medical affairs function, are firewalled from commercial targets, and build credibility precisely because prescribers experience them as a straight scientific resource rather than a promotional channel. That credibility is the whole point. A community oncologist who trusts a CSL to give an honest read on emerging data, connect them to the right academic KOL, and answer a difficult scientific question without a sales agenda will, over time, come to advocate for a therapy on their own hospital formulary or generate the real-world utilisation data payers watch. The CSL is a weak-tie connector who bridges the academic centre and the community practice, a structural position that lets scientific credibility and endorsement flow between clusters that otherwise rarely interact. If a CSL is run like a disguised sales rep, the peer trust the entire mechanic depends on collapses.
How do coverage decisions spread from one health plan to another?
Payer medical directors operate inside a dense professional community where candid peer conversation about coverage decisions is routine: the same conferences (notably AMCP), the same collaboratives, the same specialty forums. When one medical director makes an early, well-reasoned positive coverage decision for a therapy and shares the rationale in that peer setting, medical directors at other plans facing the same evidence and the same budget pressures reduce their own decision risk by following a peer they trust. This is trust transfer in the sense Van den Bulte and Wuyts describe: credibility attached to a respected source transfers to the object of the endorsement (here, the coverage decision), lowering the perceived risk for the next adopter. The mechanism is structurally identical to the investor reference call in venture capital or the peer-CFO conversation in enterprise software: a high-stakes, uncertain decision de-risked by the knowledge that a trusted peer already made it. The practical consequence is that an early coverage win with an influential plan, surfaced credibly into the peer network, becomes introduction currency that propagates across plans far faster than plan-by-plan cold engagement.
How does this differ from warm introductions in medical device sales?
The two look adjacent but involve entirely different buyers and decision architectures. Medical device sales runs through procurement: Group Purchasing Organisations control pricing access, Integrated Delivery Network purchasing gates system-wide adoption, hospital Value Analysis Committees evaluate a device before a surgeon can use it, and a clinical champion, usually the surgeon or proceduralist, drives adoption from inside the operating room. The buyer identities are supply-chain leaders, VAC members, and the surgical champion. Pharmaceutical market access, by contrast, runs through formulary inclusion and payer coverage: the P&T committee decides what goes on the formulary, medical directors at payers decide what is covered and at what tier, and formulary pharmacists assess comparative value. The advocacy lever is the KOL and the prescriber community rather than a device champion in the OR, and the decisive relationships are with academic clinical leaders, clinical science liaisons, and payer medical directors. A company selling a biologic and a company selling an implantable device are navigating different committees, different regulations, and different introduction pathways even though both ultimately depend on warm, trust-based access rather than cold outreach.
Where do compliance constraints limit warm-introduction strategy in pharma?
Heavily, and by design. The separation of medical and commercial functions means the scientific relationships that build KOL and prescriber trust (advisory boards, CSL dialogue, investigator collaboration) must be conducted through medical affairs on genuine scientific grounds, not as disguised promotion. Payments to physicians for legitimate services (consulting, advisory participation, speaking on data) are permissible but must be fair-market-value, documented, and reported under the Sunshine Act’s Open Payments system, which makes every financial physician relationship publicly visible. Anti-kickback considerations forbid structuring any endorsement or referral pathway as an inducement. The practical effect is that warm introductions in market access cannot be manufactured through commercial incentives; they have to be earned through data the clinical community genuinely finds convincing and relationships that are scientifically real. This is not a limitation to be worked around. It is the reason the mechanics work. A KOL endorsement carries weight precisely because the audience believes it reflects clinical judgment rather than a commercial arrangement, and any shortcut that compromises that belief destroys the credibility the whole strategy depends on.
What does a strong market-access introduction actually require?
It requires clinical substance the referrer genuinely believes, matched to the specific decision the recipient is making. A KOL endorsement that moves a P&T committee is not a generic statement that the drug is good; it is a specific clinical read (where the therapy fits in the treatment paradigm, which patient population benefits most, how the pivotal data compares to the standard of care) delivered by someone the committee already trusts on exactly that question. A peer coverage reference that moves a medical director is a specific account of the coverage rationale: the evidence weighed, the budget impact modelled, the utilisation management applied, and why the decision held up. In every case the introduction is only as strong as the referrer’s authentic conviction and the specificity of what they can say, which is why the KOL and CSL relationships have to be built through the scientific channel over time. The company’s role is to generate the evidence and cultivate the relationships that let credible clinical and payer voices speak specifically and honestly; the trust transfer does the rest.
Reach the clinical and payer decision-makers who gate market access
LetsBridge connects pharmaceutical and biotech teams with the clinical advocates, scientific connectors, and payer peers whose warm introductions move formulary and coverage decisions that cold promotion never will.